Video

Novel therapies extend life in patients with metastatic prostate cancer


 

Community Oncology Editor-in-Chief Dr. David Henry spoke with Dr. Nicholas Vogelzang at the Oncology Practice Summit in Las Vegas about how he treats patients with metastatic prostate cancer given the new agents that are now available and growing concerns about treatment costs and patient quality of life.

The Oncology Practice Summit was the 8th annual meeting of Community Oncology, the journal of clinical issues in community practice. Dr. Henry was a co-chair of the Summit, which was hosted this year by Community Oncology as well as The Journal of Supportive Oncology and The Oncology Report.

Recommended Reading

Abiraterone reduced morbidity in mCRPC patients
MDedge Hematology and Oncology
ASCO 2013 Genitourinary Cancers Symposium wrap up
MDedge Hematology and Oncology
Aflibercept adds toxicity and no survival benefit in mCRPC
MDedge Hematology and Oncology
Dasatinib adds no survival benefit to docetaxel in mCRPC
MDedge Hematology and Oncology
MVAC plus cystectomy boosts bladder cancer survival
MDedge Hematology and Oncology
Gene alteration lowers bladder cancer risk
MDedge Hematology and Oncology
Baldness, prostate cancer linked among black men
MDedge Hematology and Oncology
Inconclusive results seen for intermittent androgen deprivation
MDedge Hematology and Oncology
High selenium exposure may lower incidence of advanced prostate cancer
MDedge Hematology and Oncology
ACP: PSA screening's harms outweigh benefits
MDedge Hematology and Oncology

Related Articles